UCB Acquires Candid Therapeutics for $2.2 Billion, Advancing T-Cell Engager Platform for Autoimmune Diseases
Key Insights
UCB (search) has acquired Candid Therapeutics (search) for up to $2.2 billion, including $2.0 billion upfront, marking a significant investment in novel T-cell (search) engager therapies for autoimmune and inflammatory diseases (search).
Candid was founded through the merger of TRC 2004 (search) and Vignette Bio (search), with Two River (search) and Third Rock Ventures (search) playing central roles in company creation and early development.
The acquisition reflects strong investor confidence in T-cell (search) engager technology, with Candid's platform designed to redefine treatment paradigms for autoimmune conditions.
UCB (search), a global biopharmaceutical company, has announced the acquisition of Candid Therapeutics (search) for up to $2.2 billion, including $2.0 billion upfront. The deal represents a major investment in novel T-cell (search) engager (TCE) technology for treating autoimmune and inflammatory diseases (search), highlighting the growing commercial interest in this emerging therapeutic class.
Strategic Foundation and Company Formation
Candid Therapeutics (search) was established through the strategic merger of TRC 2004 (search) and Vignette Bio (search), combining complementary capabilities with an experienced management team to create a leader in autoimmune TCE therapies. Two River (search), together with Third Rock Ventures (search), played foundational roles in the company's creation, with Two River's incubation model proving instrumental in identifying differentiated biology and building the company from inception.
Through TRC 2004 (search), Two River (search) directly sourced one of Candid's lead assets from China, demonstrating the firm's ability to access global innovation and rapidly translate it into company creation. This approach enabled fast, cost-effective execution that allowed Candid to generate clinical data across multiple programs while letting clinical evidence drive strategic decisions.
Investment Ecosystem and Value Creation
The acquisition underscores the effectiveness of the Bellco Health (search) ecosystem, where company creation, early investment, and strategic collaboration converge to accelerate innovation. Vida Ventures (search) invested in Candid as part of its broader strategy of identifying and backing high-quality entrepreneurs and differentiated assets, supporting the company's progression through key scientific and strategic milestones.
"This outcome reflects the power of bringing together bold science, disciplined company building, and the right strategic partners," said Arie Belldegrun, M.D., Co-Founder of Bellco, Founder and Senior Managing Director of Vida Ventures (search), and Chairman of Two River (search). "Candid exemplifies what can happen when these capabilities come together within a broader ecosystem committed to advancing important science."
Clinical Development and Therapeutic Potential
Candid's T-cell (search) engager platform represents a novel approach to treating autoimmune and inflammatory diseases (search), with the potential to redefine current treatment paradigms. The company focused on generating robust clinical data across multiple therapeutic programs, positioning its science to reach patients at global scale through UCB (search)'s commercial infrastructure.
"Candid represents the type of company we aim to build at Two River (search)—one grounded in differentiated biology with the potential to redefine treatment paradigms," said Joshua Kazam, a Founder and Partner of Two River. "We are proud to have helped found Candid and to see its science now positioned to reach patients at global scale."
Market Momentum and Investment Trends
The Candid acquisition builds on exceptional momentum for Vida Ventures (search), which delivered one of its most productive years in 2025, completing four strategic M&A transactions and guiding a portfolio company through a successful initial public offering in a challenging market. This momentum continued into 2026 with two oversubscribed IPOs: Aktis Oncology (search) (Nasdaq: AKTS) and Avalyn Pharma (search) (Nasdaq: AVLN), signaling strong investor demand for high-quality, differentiated science.
These developments underscore Vida's multi-pillar investment strategy, which integrates deep scientific expertise with disciplined capital deployment across multiple entry points in the life sciences landscape—from company creation to traditional venture and venture-like public investing. The approach positions the firm to advance innovative science while delivering value for patients, partners, and investors.